A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)

Disease Sites:

Myelodysplastic Syndrome

Staging:

Phase III

Age Group:

Adults

Therapies:

Mol. targeted/Immunotherapy/Biologics

Drugs:

Elritercept, Placebo

Principal Investigator(s):

Kishtagari, Ashwin

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

10-09-2025

Trial Type:

Treatment

Protocol ID:

VICCHEM24599

National Clinical Trial ID:

NCT06499285

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available